22 February 2022 - Rybelsus is a new formulation of semaglutide.

Rybelsus 3 mg, 7 mg & 14 mg tablets are indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

• as monotherapy if metformin is considered inappropriate due to intolerance or contraindications
• in combination with other medicinal products for the treatment of type 2 diabetes mellitus

Read TGA prescription medicine decision summary for Rybelsus